Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ETON
stocks logo

ETON

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
22.89M
+96.52%
0.157
-622.23%
25.70M
+48.71%
0.240
-500%
28.45M
+50.31%
0.290
-390%
Estimates Revision
The market is revising No Change the revenue expectations for Eton Pharmaceuticals, Inc. (ETON) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.87%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-4.87%
In Past 3 Month
Wall Street analysts forecast ETON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETON is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ETON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETON is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.810
sliders
Low
35.00
Averages
35.00
High
35.00
Current: 16.810
sliders
Low
35.00
Averages
35.00
High
35.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$33 -> $35
2025-05-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$33 -> $35
2025-05-29
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Eton Pharmaceuticals to $35 from $33 and keeps a Buy rating on the shares after the company announced that Khindivi received FDA approval as replacement therapy in pediatric patients five years of age and older with adrenal insufficiency. The firm believes 2025 could be a year of revenue inflection for Eton.
B. Riley
Buy
maintain
$24 -> $26
2025-05-16
Reason
B. Riley
Price Target
$24 -> $26
2025-05-16
maintain
Buy
Reason
Craig-Hallum
Buy
maintain
$26 -> $28
2025-05-14
Reason
Craig-Hallum
Price Target
$26 -> $28
2025-05-14
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Eton Pharmaceuticals to $28 from $26 and keeps a Buy rating on the shares following Q1 earnings, which was another strong performance. The company reiterated an $80M run-rate goal by year-end, though the firm sees this as conservative based on current trends and has modeled slightly above this level.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$33
2025-03-19
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$33
2025-03-19
Reiterates
Strong Buy
Reason
B. Riley Securities
Madison El-Saadi
Strong Buy
Reiterates
$21 → $24
2025-03-19
Reason
B. Riley Securities
Madison El-Saadi
Price Target
$21 → $24
2025-03-19
Reiterates
Strong Buy
Reason
B. Riley raised the firm's price target on Eton Pharmaceuticals to $24 from $21 and keeps a Buy rating on the shares. The pullback following Eton's quarterly earnings report is likely due to $80M run-rate guidance vs. the $100M buy-side number, though this overlooks the conservative nature of the guidance that excludes the ET-400 contribution in FY25, providing a nice entry opportunity, the analyst tells investors in a research note. The firm sees a three-step path to $100M/$300M in annual revenue run-rate by 1Q26/1Q28.
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$23 → $26
2025-03-19
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$23 → $26
2025-03-19
Maintains
Strong Buy
Reason
Craig-Hallum raised the firm's price target on Eton Pharmaceuticals to $26 from $23 and keeps a Buy rating on the shares following the company's Investor Day and Q4 earnings results. Revenue for Q4 was $11.6M, beating Street expectations of $10.5M, with GAAP EPS at ($0.02) vs. ($0.00). Management provided 2025 guidance, targeting an $80M annual revenue run rate by year-end and a path to exceeding $100M in the near term, driven by acquisitions, Alkindi growth, and ET-400 launch, the firm notes. Investor Day showcased significant revenue potential, with management highlighting nearly $500M in peak sales from the portfolio and pipeline, adds Craig-Hallum.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Eton Pharmaceuticals Inc (ETON.O) is 16.87, compared to its 5-year average forward P/E of 23.77. For a more detailed relative valuation and DCF analysis to assess Eton Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
23.77
Current PE
16.87
Overvalued PE
116.08
Undervalued PE
-68.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-90.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
386.96
Undervalued EV/EBITDA
-567.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.84
Current PS
0.00
Overvalued PS
5.89
Undervalued PS
1.79
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ETON News & Events

Events Timeline

(ET)
2025-08-07
16:36:28
Eton Pharmaceuticals reports Q2 non-GAAP EPS 3c, consensus 2c
select
2025-07-08 (ET)
2025-07-08
06:53:07
Eton Pharmaceuticals' NDA for ET-600 solution accepted by FDA
select
2025-06-27 (ET)
2025-06-27
06:51:34
Eton Pharmaceuticals to be added to Russell 2000, Russell 3000 Indexes
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-25Newsfilter
Eton Pharmaceuticals to Host Investor Meeting at Piper Sandler Healthcare Conference in NYC
  • Executive Meeting Arrangement: Eton Pharmaceuticals' executive leadership team will host an investor meeting on December 4, 2025, at the Lotte Palace in New York, aimed at enhancing communication with investors and increasing market visibility.
  • Product Line Overview: Eton currently has eight commercial rare disease treatment products, including KHINDIVI™ and INCRELEX®, which have generated stable revenue streams and strengthened the company's market position.
  • R&D Progress: The company is also developing five late-stage product candidates, such as ET-600 and Amglidia®, which will further enrich Eton's product portfolio and potentially drive future revenue growth.
  • Industry Impact: By participating in the Piper Sandler Annual Healthcare Conference, Eton not only showcases its innovative capabilities in the rare disease sector but may also attract more investor attention, thereby enhancing the company's market valuation and investor confidence.
[object Object]
Preview
1.0
11-13Newsfilter
Eton Pharmaceuticals to Attend the 16th Annual Craig-Hallum Alpha Select Conference on November 18th

  • Company Announcement: Eton Pharmaceuticals will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York, NY.

  • Focus on Rare Diseases: Eton Pharmaceuticals specializes in developing and commercializing treatments for rare diseases, currently offering eight commercial products and five additional candidates in late-stage development.

[object Object]
Preview
9.5
11-09NASDAQ.COM
Eton Pharma (ETON) Third Quarter 2025 Earnings Call Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Eton Pharmaceuticals Inc (ETON) stock price today?

The current price of ETON is 16.81 USD — it has increased 1.88 % in the last trading day.

arrow icon

What is Eton Pharmaceuticals Inc (ETON)'s business?

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

arrow icon

What is the price predicton of ETON Stock?

Wall Street analysts forecast ETON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETON is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Eton Pharmaceuticals Inc (ETON)'s revenue for the last quarter?

Eton Pharmaceuticals Inc revenue for the last quarter amounts to 22.46M USD, increased 117.54 % YoY.

arrow icon

What is Eton Pharmaceuticals Inc (ETON)'s earnings per share (EPS) for the last quarter?

Eton Pharmaceuticals Inc. EPS for the last quarter amounts to -0.07 USD, decreased -450.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Eton Pharmaceuticals Inc (ETON)'s fundamentals?

The market is revising No Change the revenue expectations for Eton Pharmaceuticals, Inc. (ETON) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.87%.
arrow icon

How many employees does Eton Pharmaceuticals Inc (ETON). have?

Eton Pharmaceuticals Inc (ETON) has 31 emplpoyees as of December 05 2025.

arrow icon

What is Eton Pharmaceuticals Inc (ETON) market cap?

Today ETON has the market capitalization of 449.19M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free